Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,604.00
Ask: 1,604.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,600.50
High: 1,612.50
Low: 1,591.00
Prev. Close: 1,595.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

13 Dec 2023 15:30

RNS Number : 6543W
GSK PLC
13 December 2023

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

8 (partnership shares)

£14.4015

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

9 (partnership shares)

£14.4015

9 (matching shares)

d)

Aggregated information

Aggregated volume Price

18 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.4015

8 (partnership shares)

£14.4015

8 (matching shares)

d)

Aggregated information

Aggregated volume Price

16 Ordinary Shares

£14.4015

e)

Date of the transaction

2023-12-11

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFEFSDEDSEEE
Date   Source Headline
1st Feb 201811:52 amRNSTotal Voting Rights
26th Jan 201812:30 pmRNSGSK's Shingrix - positive CHMP opinion in Europe
26th Jan 20189:00 amRNSGSK's Relvar Ellipta - positive CHMP opinion
23rd Jan 20183:22 pmRNSDirector/PDMR Shareholding
19th Jan 20185:19 pmRNSDirector/PDMR Shareholding
19th Jan 20185:17 pmRNSDirector/PDMR Shareholding
16th Jan 20185:48 pmRNSDirector/PDMR Shareholding
15th Jan 20185:59 pmRNSDirector/PDMR Shareholding
15th Jan 20185:54 pmRNSDirector/PDMR Shareholding
15th Jan 20185:34 pmRNSDirector/PDMR Shareholding
15th Jan 20189:18 amRNSDirector/PDMR Shareholding
15th Jan 20189:04 amRNSDirector/PDMR Shareholding
11th Jan 20183:33 pmRNSDirector/PDMR Shareholding
2nd Jan 20182:00 pmRNSDirector Shareholding
2nd Jan 20181:54 pmRNSTotal Voting Rights
21st Dec 20179:02 amRNSFDA approval - on ICS/LABA combinations in asthma
18th Dec 20174:21 pmRNSDirector/PDMR Shareholding
15th Dec 20177:00 amRNSTransfer of Shares out of Treasury
12th Dec 20174:50 pmRNSDirector/PDMR Shareholding
12th Dec 20174:16 pmRNSGSK gains US approval for Nucala to treat EGPA
12th Dec 20177:00 amRNSPromising data for GSK2857916 at ASH meeting
6th Dec 20177:00 amRNSNew data - Shingrix in immune-compromised patients
1st Dec 20171:47 pmRNSDirector/PDMR Shareholding
1st Dec 20171:44 pmRNSDirector/PDMR Shareholding
1st Dec 20171:37 pmRNSTotal Voting Rights
30th Nov 20177:00 amRNSViiV starts Phase 3 HIV prevention study in women
27th Nov 20172:03 pmRNSViiV starts Phase 3 longacting HIV treatment study
23rd Nov 20177:00 amRNSGSK submit IMPACT data to support Trelegy Ellipta
22nd Nov 20177:00 amRNSViiV Juluca approved in US as first 2-drug regimen
21st Nov 20172:21 pmRNSGSK publishes 2018 dividend dates
16th Nov 20177:00 amRNSTrelegy Ellipta EU approval for treatment of COPD
10th Nov 20171:15 pmRNSDirector/PDMR Shareholding
9th Nov 20175:00 pmRNSBlock listing Interim Review
8th Nov 20172:00 pmRNSDirectorate Change
8th Nov 20172:00 pmRNSDirectorate Change
7th Nov 20173:01 pmRNSUS regulatory application for mepolizumab in COPD
2nd Nov 20177:35 amRNSBCMA receives FDA Breakthrough Therapy Designation
1st Nov 201712:01 pmRNSTotal Voting Rights
1st Nov 201711:01 amRNSSuperiority of Anoro Ellipta demonstrated for COPD
25th Oct 20175:46 pmRNSCDC ACIP makes recommendations for use of Shingrix
25th Oct 20173:21 pmRNSDirector/PDMR Shareholding
25th Oct 201712:00 pmRNS3rd Quarter Results
23rd Oct 20177:00 amRNSGSK's Shingrix Receives US FDA Approval
20th Oct 20174:12 pmRNSDirector/PDMR Shareholding
20th Oct 20174:08 pmRNSDirector/PDMR Shareholding
16th Oct 20174:52 pmRNSDirector/PDMR Shareholding
16th Oct 20174:42 pmRNSDirector/PDMR Shareholding
16th Oct 20174:40 pmRNSDirector/PDMR Shareholding
16th Oct 20174:40 pmRNSDirector/PDMR Shareholding
16th Oct 201711:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.